A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

Registry ID

C5701009

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PFIZER CANADA ULC

Last update

2026-07-21

Conditions

• MUSCLE-INVASIVE BLADDER CANCER

Related clinical trials

• AN OPEN-LABEL, SINGLE-ARM, GLOBAL STUDY OF PERIOPERATIVE DURVALUMAB WITH CISPLATIN-BASED NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (NIAGARA-2)
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PERIOPERATIVE ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB (MK-3475) VERSUS NEOADJUVANT GEMCITABINE AND CISPLATIN IN CISPLATIN-ELIGIBLE PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER (KEYNOTE-B15 /EV-304)
• A PHASE 3 RANDOMIZED STUDY OF CYSTECTOMY PLUS PERIOPERATIVE PEMBROLIZUMAB VERSUS CYSTECTOMY ALONE IN CISPLATIN-INELIGIBLE PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER (KEYNOTE-905)
• A RANDOMIZED PHASE II TRIAL ASSESSING TRIMODALITY THERAPY WITH OR WITHOUT ADJUVANT DURVALUMAB TO TREAT PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER

View on source registry